Mitotic rate and sentinel lymph node tumor burden topography: Integration into melanoma staging and stratification use in clinical trials

Journal of Clinical Oncology

Volumn 29, Issue 16, 2011, Pages 2137-2141

  Averbook, Bruce J ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CANCER VACCINE; DACARBAZINE; DASATINIB; IPILIMUMAB; SORAFENIB;

CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); CYSTECTOMY; DISEASE FREE SURVIVAL; EDITORIAL; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MELANOMA; MITOSIS; PRIORITY JOURNAL; PROGNOSIS; SENTINEL LYMPH NODE; SURVIVAL RATE; TOPOGRAPHY; TUMOR VOLUME;

CELL PROLIFERATION; HUMANS; LYMPHATIC METASTASIS; MELANOMA; MITOSIS; MITOTIC INDEX; NEOPLASM STAGING; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY;

EID: 79957931629     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.1982     Document Type: Editorial

References (55)

1. Balch CM, Buzaid AC, Soong S-J, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648, 2001 (Pubitemid 32786276)
2. Balch CM, Soong S-J, Gershenwald JE, et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622-3634, 2001 (Pubitemid 32786275)
3. Rousseau DL Jr, Ross MI, Johnson MM, et al: Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol 10:569-574, 2003 (Pubitemid 40486922)
4. Thompson JF, Soong S-J, Balch CM, et al: Prognostic significance of mitotic rate in localized primary cutaneous melanoma: An analysis of patients in the multi-institutional American Joint Committee on Cancer Melanoma Staging Database. J Clin Oncol 29:2199-2205, 2011
5. van der Ploeg APT, van Akkooi ACJ, Rutkowski P, et al: Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol 29:2206-2214, 2011
6. Balch CM, Gershenwald JE, Soong S-J, et al: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199-6206, 2009
7. Azzola MF, Shaw HM, Thompson JF, et al: Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: An analysis of 3661 patients from a single center. Cancer 97:1488-1498, 2003 (Pubitemid 36297779)
8. Francken AB, Shaw HM, Thompson JF, et al: The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol 11:426-433, 2004 (Pubitemid 40486754)
9. Gimotty PA, Guerry D, Ming ME, et al: Thin primary cutaneous malignant melanoma: A prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol 22:3668-3676, 2004 (Pubitemid 41095205)
10. Sondak VK, Taylor JM, Sabel MS, et al: Mitotic rate and younger age are predictors of sentinel lymph node positivity: Lessons learned from the generation of a probabilistic model. Ann Surg Oncol 11:247-258, 2004 (Pubitemid 40486764)
11. Thompson JF, Shaw HM: Should tumor mitotic rate and patient age, as well as tumor thickness, be used to select melanoma patients for sentinel node biopsy? Ann Surg Oncol 11:233-235, 2004
12. Barnhill RL, Katzen J, Spatz A, et al: The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. J Cutan Pathol 32:268-273, 2005 (Pubitemid 40459928)
13. Kesmodel SB, Karakousis GC, Botbyl JD, et al: Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol 12:449-458, 2005 (Pubitemid 40884259)
14. Scolyer RA, Shaw HM, Thompson JF, et al: Interobserver reproducibility of histopathologic prognostic variables in primary cutaneous melanomas. Am J Surg Pathol 27:1571-1576, 2003 (Pubitemid 37486620)
15. Balch CM, Murad TM, Soong S-J, et al: A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg 188:732-742, 1978
16. Balch CM, Soong S-J, Milton GW, et al: A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg 196:677-684, 1982 (Pubitemid 13208367)
17. Averbook BJ, Russo LJ, and Mansour EG: A long-term analysis of 620 patients with malignant melanoma at a major referral center. Surgery 124:746-756; discussion 755-756, 1998
18. Averbook BJ, Fu P, Rao JS, et al: A long-term analysis of 1018 patients with melanoma by classic Cox regression and tree-structured survival analysis at a major referral center: Implications on the future of cancer staging. Surgery 132:589-604, 2002 (Pubitemid 35247321)
19. McKinnon JG, Yu XQ, McCarthy WH, et al: Prognosis for patients with thin cutaneous melanoma: Long-term survival data from the New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer 98:1223-1231, 2003 (Pubitemid 37099907)
20. Averbook BJ: Invited review: Melanoma in the older person. Oncology 18:1196-1197, 2004
21. Lasithiotakis K, Leiter U, Meier F, et al: Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer 112:1795-1804, 2008 (Pubitemid 351536840)
22. Stucky CC, Gray RJ, Dueck AC, et al: Risk factors associated with local and in-transit recurrence of cutaneous melanoma. Am J Surg 200:770-774; discussion 774-775, 2010
23. Tsai S, Balch C, Lange J: Epidemiology and treatment of melanoma in elderly patients. Nat Rev Clin Oncol 7:148-152, 2010
24. Mays MP, Martin RC, Burton A, et al: Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy? Cancer 116:1535-1544, 2010
25. Balch CM, Gershenwald JE, Soong S-J, et al: Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28:2452-2459, 2010
26. Romano E, Scordo M, Dusza SW, et al: Site and timing of first relapse in stage III melanoma patients: Implications for follow-up guidelines. J Clin Oncol 28:3042-3047, 2010
27. Lasithiotakis KG, Petrakis IE, Garbe C: Cutaneous melanoma in the elderly: epidemiology, prognosis and treatment. Melanoma Res 20:163-170, 2010
28. Wiener M, Acland KM, Shaw HM, et al: Sentinel node positive melanoma patients: Prediction and prognostic significance of nonsentinel node metastases and development of a survival tree model. Ann Surg Oncol 17:1995-2005, 2010
29. Soong S-J, Ding S, Coit D, et al: Predicting survival outcome of localized melanoma: An electronic prediction tool based on the AJCC Melanoma Database. Ann Surg Oncol 17:2006-2014, 2010
30. Spillane AJ, Cheung BL, Winstanley J, et al: Lymph node ratio provides prognostic information in addition to American joint committee on cancer N stage in patients with melanoma, even if quality of surgery is standardized. Ann Surg 253:109-115, 2011
31. Kretschmer L, Starz H, Thoms KM, et al: Age as a key factor influencing metastasizing patterns and disease-specific survival after sentinel lymph node biopsy for cutaneous melanoma. Int J Cancer doi: 10.1002/ijc.25747, 2011
32. Ranieri JM, Wagner JD, Azuaje R, et al: Prognostic importance of lymph node tumor burden in melanoma patients staged by sentinel node biopsy. Ann Surg Oncol 9:975-981, 2002 (Pubitemid 35424631)
33. Carlson GW, Murray DR, Lyles RH, et al: The amount of metastatic melanoma in a sentinel lymph node: Does it have prognostic significance? Ann Surg Oncol 10:575-581, 2003
34. Reeves ME, Delgado R, Busam KJ, et al: Prediction of nonsentinel lymph node status in melanoma. Ann Surg Oncol 10:27-31, 2003
35. Lee JH, Essner R, Torisu-Itakura H, et al: Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol 22:3677-3684, 2004 (Pubitemid 41095206)
36. Scolyer RA, Li LX, McCarthy SW, et al: Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma. Am J Clin Pathol 122:532-539, 2004 (Pubitemid 39281249)
37. Cochran AJ, Wen DR, Huang RR, et al: Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol 17:747-755, 2004 (Pubitemid 38843356)
38. Sabel MS, Griffith K, Sondak VK, et al: Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg 201:37-47, 2005 (Pubitemid 40840562)
39. van Akkooi AC, de Wilt JH, Verhoef C, et al: Clinical relevance of melanoma micrometastases (< 0.1 mm) in sentinel nodes: Are these nodes to be considered negative? Ann Oncol 17:1578-1585, 2006
40. Debarbieux S, Duru G, Dalle S, et al: Sentinel lymph node biopsy in melanoma: A micromorphometric study relating to prognosis and completion lymph node dissection. Br J Dermatol 157:58-67, 2007 (Pubitemid 46934258)
41. Scheri RP, Essner R, Turner RR, et al: Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. Ann Surg Oncol 14:2861-2866, 2007 (Pubitemid 47460638)
42. Page AJ, Carlson GW, Delman KA, et al: Prediction of nonsentinel lymph node involvement in patients with a positive sentinel lymph node in malignant melanoma. Am Surg 73:674-679, 2007
43. Glumac N, Hocevar M, Zadnik V, et al: Sentinel lymph node micrometastasis may predict non-sentinel involvement in cutaneous melanoma patients. J Surg Oncol 98:46-48, 2008 (Pubitemid 351976953)
44. van Akkooi AC, Nowecki ZI, Voit C, et al: Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: A multicenter study in 388 patients with positive sentinel nodes. Ann Surg 248:949-955, 2008
45. Rossi CR, De Salvo GL, Bonandini E, et al: Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node. Ann Surg Oncol 15:1202-1210, 2008
46. Frankel TL, Griffith KA, Lowe L, et al: Do micromorphometric features of metastatic deposits within sentinel nodes predict nonsentinel lymph node involvement in melanoma? Ann Surg Oncol 15:2403-2411, 2008
47. Guggenheim M, Dummer R, Jung FJ, et al: The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma: A retrospective analysis of 392 cases. Br J Cancer 98:1922-1928, 2008
48. Gershenwald JE, Andtbacka RH, Prieto VG, et al: Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol 26:4296-4303, 2008
49. van der Ploeg IM, Kroon BB, Antonini N, et al: Comparison of three micromorphometric pathology classifications of melanoma metastases in the sentinel node. Ann Surg 250:301-304, 2009
50. Francischetto T, Spector N, Neto Rezende JF, et al: Influence of sentinel lymph node tumor burden on survival in melanoma. Ann Surg Oncol 17:1152-1158, 2010
51. Morton DL, Cochran AJ, Thompson JF, et al: Sentinel node biopsy for early-stage melanoma: Accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 242:302-313, 2005 (Pubitemid 41306595)
52. Morton DL, Thompson JF, Cochran AJ, et al: Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 355:1307-1317, 2006 (erratum in: N Engl J Med 355:1944, 2006)
53. Amersi F, Morton DL: The role of sentinel lymph node biopsy in the management of melanoma. Adv Surg 41:241-256, 2007
54. US National Institutes of Health ClinicalTrials.gov: Multicenter Selective Lymphadenectomy Trial II (MSLT-II). http://clinicaltrials.gov/ct/show/ NCT00297895
55. European Organisation for Research and Treatment of Cancer Melanoma Group: MINITUB registration study. http://www.melanomagroup.eu/content/view/101/ 117/